JP2005531557A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005531557A5 JP2005531557A5 JP2004505050A JP2004505050A JP2005531557A5 JP 2005531557 A5 JP2005531557 A5 JP 2005531557A5 JP 2004505050 A JP2004505050 A JP 2004505050A JP 2004505050 A JP2004505050 A JP 2004505050A JP 2005531557 A5 JP2005531557 A5 JP 2005531557A5
- Authority
- JP
- Japan
- Prior art keywords
- effective
- compound
- use according
- opiate receptor
- appetite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 19
- 230000002496 gastric effect Effects 0.000 claims description 13
- 206010061428 decreased appetite Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 102000003840 Opioid Receptors Human genes 0.000 claims description 11
- 108090000137 Opioid Receptors Proteins 0.000 claims description 11
- 208000022531 anorexia Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 239000002830 appetite depressant Substances 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 8
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 6
- 208000032841 Bulimia Diseases 0.000 claims description 6
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 6
- 208000007542 Paresis Diseases 0.000 claims description 6
- 235000019789 appetite Nutrition 0.000 claims description 6
- 230000036528 appetite Effects 0.000 claims description 6
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical group C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 6
- 206010006895 Cachexia Diseases 0.000 claims description 5
- 206010017753 Gastric atony Diseases 0.000 claims description 5
- 206010021518 Impaired gastric emptying Diseases 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 208000001288 gastroparesis Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 235000009088 Citrus pyriformis Nutrition 0.000 claims description 4
- 244000131522 Citrus pyriformis Species 0.000 claims description 4
- 208000030814 Eating disease Diseases 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 4
- 229960003609 cathine Drugs 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 229960000395 phenylpropanolamine Drugs 0.000 claims description 4
- 208000037804 stenosis Diseases 0.000 claims description 4
- 230000036262 stenosis Effects 0.000 claims description 4
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 3
- 229960002179 ephedrine Drugs 0.000 claims description 3
- 206010033799 Paralysis Diseases 0.000 claims description 2
- JHLHNYVMZCADTC-LOSJGSFVSA-N asimadoline Chemical compound C([C@@H](N(C)C(=O)C(C=1C=CC=CC=1)C=1C=CC=CC=1)C=1C=CC=CC=1)N1CC[C@H](O)C1 JHLHNYVMZCADTC-LOSJGSFVSA-N 0.000 claims 6
- 229950002202 asimadoline Drugs 0.000 claims 6
- 229940075993 receptor modulator Drugs 0.000 claims 6
- -1 fedotodine Chemical compound 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims 2
- 229960001571 loperamide Drugs 0.000 claims 2
- 230000000291 postprandial effect Effects 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 229960004425 sibutramine Drugs 0.000 claims 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- JKYJSFISYHSNOE-UHFFFAOYSA-N 2-[3-[1-[[2-(3,4-dichlorophenyl)-1-oxoethyl]-methylamino]-2-(1-pyrrolidinyl)ethyl]phenoxy]acetic acid Chemical compound C=1C=C(Cl)C(Cl)=CC=1CC(=O)N(C)C(C=1C=C(OCC(O)=O)C=CC=1)CN1CCCC1 JKYJSFISYHSNOE-UHFFFAOYSA-N 0.000 claims 1
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 235000014676 Phragmites communis Nutrition 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- UPNUIXSCZBYVBB-JVFUWBCBSA-N alvimopan Chemical compound C([C@@H](CN1C[C@@H]([C@](CC1)(C)C=1C=C(O)C=CC=1)C)C(=O)NCC(O)=O)C1=CC=CC=C1 UPNUIXSCZBYVBB-JVFUWBCBSA-N 0.000 claims 1
- 229960004516 alvimopan Drugs 0.000 claims 1
- 208000024330 bloating Diseases 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- MVKIWCDXKCUDEH-QFIPXVFZSA-N fedotozine Chemical compound C([C@](CC)(N(C)C)C=1C=CC=CC=1)OCC1=CC(OC)=C(OC)C(OC)=C1 MVKIWCDXKCUDEH-QFIPXVFZSA-N 0.000 claims 1
- 229950008449 fedotozine Drugs 0.000 claims 1
- 235000019525 fullness Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 1
- 229960005301 pentazocine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- DLNKOYKMWOXYQA-IONNQARKSA-N cathine Chemical compound C[C@H](N)[C@@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-IONNQARKSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 201000000660 Pyloric Stenosis Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- DYWNLSQWJMTVGJ-DKXTVVGFSA-N (1s,2s)-2-amino-1-phenylpropan-1-ol;hydron;chloride Chemical compound Cl.C[C@H](N)[C@@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-DKXTVVGFSA-N 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010052105 Gastrointestinal hypomotility Diseases 0.000 description 1
- 206010018007 Gastrointestinal stenosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229960003466 sibutramine hydrochloride Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02011047 | 2002-05-17 | ||
| PCT/EP2003/004428 WO2003097051A2 (en) | 2002-05-17 | 2003-04-28 | Use of compounds that are effective as selective opiate receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005531557A JP2005531557A (ja) | 2005-10-20 |
| JP2005531557A5 true JP2005531557A5 (https=) | 2007-05-17 |
Family
ID=29433078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505050A Pending JP2005531557A (ja) | 2002-05-17 | 2003-04-28 | 選択的オピエート受容体モジュレーターとして効果的な化合物の使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050176746A1 (https=) |
| EP (2) | EP1505974B1 (https=) |
| JP (1) | JP2005531557A (https=) |
| KR (1) | KR101108014B1 (https=) |
| CN (2) | CN101310723A (https=) |
| AR (1) | AR040028A1 (https=) |
| AT (1) | ATE429226T1 (https=) |
| AU (1) | AU2003242527B2 (https=) |
| BR (1) | BR0309969A (https=) |
| CA (1) | CA2486000A1 (https=) |
| DE (1) | DE60327315D1 (https=) |
| DK (1) | DK1505974T3 (https=) |
| ES (1) | ES2325782T3 (https=) |
| MX (1) | MXPA04011333A (https=) |
| PE (1) | PE20040455A1 (https=) |
| PL (1) | PL371596A1 (https=) |
| RU (1) | RU2336871C2 (https=) |
| TW (1) | TWI314053B (https=) |
| WO (1) | WO2003097051A2 (https=) |
| ZA (1) | ZA200410160B (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10259245A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
| SG168407A1 (en) | 2003-01-28 | 2011-02-28 | Ironwood Pharmaceuticals Inc | Methods and compositions for the treatment of gastrointestinal disorders |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1870096A3 (en) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| EP1617832B1 (en) | 2003-04-29 | 2008-03-12 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| US20080090859A1 (en) * | 2003-10-30 | 2008-04-17 | Tioga Pharmaceuticals, Inc. | Use of Selective Opiate Receptor Modulators In the Treatment Of Neuropathy |
| CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| CN101677997B (zh) * | 2007-03-30 | 2012-05-09 | 泰奥加制药公司 | 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2527360B1 (en) | 2007-06-04 | 2015-10-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| CA2994066A1 (en) | 2008-12-03 | 2010-06-10 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| SI2384318T1 (en) | 2008-12-31 | 2018-03-30 | Ardelyx, Inc. | MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT |
| RU2413512C1 (ru) * | 2009-07-29 | 2011-03-10 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" | Средство, обладающее каппа-опиоидной агонистической активностью |
| MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
| WO2012012410A2 (en) * | 2010-07-19 | 2012-01-26 | Dr. Reddy's Laboratories Ltd. | Kappa opioid receptor agonists |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| ES2664873T3 (es) | 2011-03-01 | 2018-04-23 | Synergy Pharmaceuticals Inc. | Proceso de preparación de agonistas de guanilato ciclasa C |
| CN110893181A (zh) | 2012-06-06 | 2020-03-20 | 纳丙药业有限责任公司 | 治疗超重和肥胖症的方法 |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| MX366293B (es) | 2012-08-21 | 2019-07-04 | Ardelyx Inc | Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal. |
| US9675587B2 (en) | 2013-03-14 | 2017-06-13 | Allergan Holdings Unlimited Company | Opioid receptor modulator dosage formulations |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| LT2983667T (lt) | 2013-04-12 | 2019-07-10 | Ardelyx, Inc. | Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai |
| SI3004138T1 (sl) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Limited | Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo |
| EA023231B1 (ru) * | 2013-07-18 | 2016-05-31 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН) | Применение агониста каппа опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения синдрома отмены никотина |
| US20160250277A1 (en) * | 2013-10-28 | 2016-09-01 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| EA201991676A1 (ru) | 2017-01-09 | 2020-01-30 | Арделикс, Инк. | Ингибиторы nhe-опосредованного антипорта |
| CA3049678A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889860A (en) * | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
| DE3935371A1 (de) | 1988-12-23 | 1990-07-05 | Merck Patent Gmbh | Stickstoffhaltige ringverbindungen |
| DE4034785A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | 1-(2-arylethyl)-pyrrolidine |
| US5389686A (en) * | 1989-02-20 | 1995-02-14 | Jouveinal Sa | Analgesic properties of fedotozine |
| DE4215213A1 (de) | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Arylacetamide |
| DE4215231C1 (en) | 1992-05-09 | 1993-05-13 | Dornier Luftfahrt Gmbh, 8031 Wessling, De | Arrangement for mfg. fibre reinforced thermoplastic components - including unit for accommodating component, pressurising unit for assembled component and heating unit |
| DE19523502A1 (de) * | 1995-06-28 | 1997-01-02 | Merck Patent Gmbh | Kappa-Opiatagonisten für entzündliche Darmerkrankungen |
| DE19531464A1 (de) * | 1995-08-26 | 1997-02-27 | Merck Patent Gmbh | N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid |
| IL135258A0 (en) * | 1997-09-26 | 2001-05-20 | Noven Pharma | Bioadhesive compositions and methods for topical administration of active agents |
| US20010051181A1 (en) * | 1997-12-22 | 2001-12-13 | Van Osdol William W. | Novel formulations for the transdermal administration of asimadoline |
| JPH11343244A (ja) * | 1998-03-30 | 1999-12-14 | Taisho Pharmaceut Co Ltd | 経口用組成物 |
| JP2000080047A (ja) * | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
| WO2000004050A2 (en) * | 1998-07-14 | 2000-01-27 | Janssen Pharmaceutica N.V. | Neurotrophic growth factor |
| ATE289586T1 (de) * | 1999-03-01 | 2005-03-15 | Pfizer Prod Inc | Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor |
| WO2001097753A2 (en) * | 2000-06-19 | 2001-12-27 | Eisai Co. Ltd. | Novel methods using pyridine derivatives |
| GB0015562D0 (en) * | 2000-06-23 | 2000-08-16 | Pfizer Ltd | Heterocycles |
| DE10030893A1 (de) * | 2000-06-23 | 2002-01-03 | Henkel Kgaa | Paraaminophenol-Derivate und deren Verwendung |
| US6262062B1 (en) * | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
| US6780891B2 (en) * | 2001-11-30 | 2004-08-24 | Sepracor Inc. | Tramadol analogs and uses thereof |
-
2003
- 2003-04-28 US US10/514,887 patent/US20050176746A1/en not_active Abandoned
- 2003-04-28 MX MXPA04011333A patent/MXPA04011333A/es active IP Right Grant
- 2003-04-28 KR KR1020047018468A patent/KR101108014B1/ko not_active Expired - Fee Related
- 2003-04-28 BR BR0309969-5A patent/BR0309969A/pt not_active Application Discontinuation
- 2003-04-28 AU AU2003242527A patent/AU2003242527B2/en not_active Ceased
- 2003-04-28 EP EP03752716A patent/EP1505974B1/en not_active Expired - Lifetime
- 2003-04-28 EP EP09158047A patent/EP2074997A1/en not_active Withdrawn
- 2003-04-28 DK DK03752716T patent/DK1505974T3/da active
- 2003-04-28 PL PL03371596A patent/PL371596A1/xx not_active Application Discontinuation
- 2003-04-28 AT AT03752716T patent/ATE429226T1/de not_active IP Right Cessation
- 2003-04-28 CN CNA2008101295692A patent/CN101310723A/zh active Pending
- 2003-04-28 WO PCT/EP2003/004428 patent/WO2003097051A2/en not_active Ceased
- 2003-04-28 JP JP2004505050A patent/JP2005531557A/ja active Pending
- 2003-04-28 CN CNB038111373A patent/CN100411618C/zh not_active Expired - Fee Related
- 2003-04-28 ES ES03752716T patent/ES2325782T3/es not_active Expired - Lifetime
- 2003-04-28 RU RU2004137091/15A patent/RU2336871C2/ru not_active IP Right Cessation
- 2003-04-28 DE DE60327315T patent/DE60327315D1/de not_active Expired - Lifetime
- 2003-04-28 CA CA002486000A patent/CA2486000A1/en not_active Abandoned
- 2003-05-12 TW TW092112843A patent/TWI314053B/zh not_active IP Right Cessation
- 2003-05-13 PE PE2003000457A patent/PE20040455A1/es not_active Application Discontinuation
- 2003-05-16 AR ARP030101709A patent/AR040028A1/es unknown
-
2004
- 2004-12-15 ZA ZA2004/10160A patent/ZA200410160B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005531557A5 (https=) | ||
| RU2004137091A (ru) | Применение соединений, которые являются эффективными как селективные модуляторы опиатного рецептора | |
| RS60152B1 (sr) | Tapentadol za sprečavanje i lečenje depresije i anksioznosti | |
| CN1468111A (zh) | 治疗急性、慢性疼痛和/或神经病性疼痛和偏头痛的药物组合物 | |
| WO2011008298A2 (en) | Novel axomadol dosage forms | |
| JP2010515754A (ja) | Ｒ−バクロフェンのプロドラッグの徐放性経口剤形及び治療方法 | |
| CN1141937C (zh) | 含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物 | |
| JP5828609B2 (ja) | 持続性解熱鎮痛消炎剤 | |
| JPWO2002053153A1 (ja) | 神経因性疼痛治療及び予防薬 | |
| CA2403994A1 (en) | Nasal administration of agents for the treatment of gastroparesis | |
| WO2004096202A1 (en) | Pharmaceutical formulation comprising anti-obesity agent and acidulant | |
| US20090048233A1 (en) | Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination | |
| TWI844074B (zh) | 氯胺酮衍生物之醫藥組成物及口服劑型 | |
| JP7656339B2 (ja) | 疼痛を緩和するためのイブプロフェン及びトラマドールの組合せ | |
| KR20010099648A (ko) | 신규 조성물 | |
| WO2005067909A1 (en) | Combination therapy with mecamylamine for the treatment of mood disorders | |
| JP2015516449A (ja) | （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびパラセタモールまたはプロパセタモールを含む医薬組成物 | |
| JP2008106028A (ja) | 慢性疼痛の治療におけるフリバンセリンの使用 | |
| WO2001034140A1 (en) | Pharmaceutical formulation | |
| JP2826843B2 (ja) | 消化管運動賦活剤 | |
| JP2711776B2 (ja) | 顎関節症治療剤 | |
| WO2004058237A1 (en) | Therapeutic use of sibutramine and analogues thereof | |
| JP2008007502A (ja) | 肥満治療剤並びに肥満の治療及び予防方法 | |
| KR20220110259A (ko) | 통증 질환에 사용하기 위한 미르타자핀 및 티자니딘 배합물 | |
| HK40067137B (en) | Combination of ibuprofen and tramadol for relieving pain |